Nutra Pharma has announced that it will be presenting and exhibiting at the upcoming
Accredited Members, Inc. Winter 2010 Small Cap/Micro Cap Investment Conference in Scottsdale, Arizona, and at The World MoneyShow in Orlando, Florida
Nutra Pharma Corporation.Press Release Source: Nutra Pharma Corp. On Thursday January 14, 2010, 9:00 am PLANTATION, Fla.--Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it will be presenting and exhibiting at the upcoming Accredited Members, Inc. Winter 2010 Small Cap/Micro Cap Investment Conference in Scottsdale, Arizona, and at The World MoneyShow in Orlando, Florida.
“This is an exciting time for Nutra Pharma as we continue to rollout our first drug products and begin generating our first significant revenues in the history of the Company,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “These conferences provide excellent opportunities to expand our presence within the investment community and share our unique and exciting growth story,” he concluded.
The Accredited Members, Inc. Winter 2010 Small Cap/Micro Cap Investment Conference, which is scheduled for February 1st to February 3rd 2010, will be hosted at the Four Seasons Resort in Scottsdale Arizona. The World MoneyShow is scheduled for February 3rd to February 6th 2010 and will be held at the Gaylord Palms Hotel and Convention Center in Orlando, Florida.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
http://www.NutraPharma.com
Please call Undiscovered Equities at 1-800-404-8982
www.undiscoveredequities.com
101 Plaza Real South, Suite 212
Boca Raton, FL 33432
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment